Last updated: February 13, 2026
What is the drug identified by NDC 59212-0249?
NDC 59212-0249 refers to Tazverik (tazemetostat), developed by Epizyme Inc. It is an oral, small-molecule EZH2 inhibitor approved by the FDA in July 2020 for treating epithelioid sarcoma and follicular lymphoma with specific EZH2 mutations.
Market Scope and Current Position
Indications:
- Epithelioid sarcoma (uncommon soft tissue cancer)
- Follicular lymphoma (a subtype of non-Hodgkin lymphoma) with EZH2 mutation
Market Penetration:
- Launched in July 2020
- Approved in the U.S. and several European countries
- Limited until recent approvals for broader indications
Competitors:
- Tazverik competes mainly with existing therapies like chemotherapy, immunotherapy, and emerging EZH2 inhibitors such as GSK2816126 and kivivmab (combinatory approaches).
Therapeutic Niche:
- Niche targeting rare cancers with high unmet needs and specific genetic mutations
- Market controlled by precision medicine protocols
Estimated Market Size
Global Sales Data (2022-2023):
- Estimated U.S. sales: $100 million in 2022, projected to reach $150 million in 2023.
- European and Asian markets: emerging, combined adding approximately $30 million annually.
Patient Population Estimates:
- Epithelioid sarcoma: ~200-300 patients in the U.S. annually
- Follicular lymphoma with EZH2 mutation: an estimated 5,000-6,000 patients globally, with the EZH2 mutation present in about 20-30% of cases.
Pricing Benchmarks:
- Initial wholesale acquisition cost (WAC): roughly $13,500-$15,000 per month per patient.
- Estimated annual treatment cost: $160,000 - $180,000.
Pricing Trends and Projections
Current Pricing Dynamics:
- The drug’s pricing reflects premium positioning within targeted therapies.
- Payers impose extensive prior authorization due to high costs and specific genetic testing requirements.
Future Price Trajectories:
- Expectations:
- Slight decreases in net prices due to increased competition and biosimilar entry (if applicable).
- Possible tiered pricing in international markets based on healthcare budgets and negotiation power.
- Projected Price Range (2023-2027):
- WAC remains stable around $14,000/month.
- Average negotiated price (post-reimbursement and discounts): $10,000 - $12,000/month.
Impact of Market Expansion:
- Broader indications, such as frontline therapy for follicular lymphoma, could increase patient volume by 30-50%.
- Patent protection extends to 2030, precluding generics but enabling potential biosimilar or me-too entrants post-expiry.
Revenue Projections (2023-2027)
| Year |
Estimated U.S. Sales |
Estimated International Sales |
Total Revenue |
Notes |
| 2023 |
$150 million |
$50 million |
$200 million |
Continued growth, steady pricing |
| 2024 |
$200 million |
$75 million |
$275 million |
Indication expansion, new approvals |
| 2025 |
$250 million |
$100 million |
$350 million |
Increased acceptance, payer negotiations |
| 2026 |
$300 million |
$130 million |
$430 million |
Market maturity, volume growth |
| 2027 |
$350 million |
$160 million |
$510 million |
Full adoption in approved indications |
Risk Factors Impacting Price and Market Dynamics
- Regulatory shifts: Expanded indications or new approvals could dilute pricing power due to increased volume.
- Biosimilar and generic competition: Patent expiry or approval of equivalents could lead to price erosion post-2030.
- Market penetration: Delay in payer reimbursement or clinician adoption can limit growth.
- Pricing pressures: Payers enforce discounts and high-tier reimbursement policies, potentially reducing net pricing.
Conclusion
Tazverik (NDC 59212-0249) is positioned within a niche, high-cost segment with solid growth prospects driven by expanding indications and targeted therapy protocols. Current sales are around $200 million annually with stable, premium pricing. Future revenue hinges on regulatory approvals, market access, and competitive landscape evolution. Price remains relatively stable with moderate downward pressure anticipated once broader indications and competitive pressures materialize.
Key Takeaways
- Tazverik's sales are $150-$200 million annually, primarily driven by its niche cancer indications and targeted therapy profile.
- Pricing trends show stable monthly costs around $14,000, with potential reductions due to negotiations and competition.
- Market expansion depends on indication approvals, especially in follicular lymphoma, where the patient pool may grow three-fold.
- Patent protection extends through 2030, post which biosimilar entry could erode prices.
- Revenue growth prospects remain strong until market saturation or competitive challenges dampen pricing.
FAQs
Q1: What are the main indications for NDC 59212-0249?
A: Epithelioid sarcoma and follicular lymphoma with EZH2 mutations.
Q2: How does the current pricing compare to other targeted cancer therapies?
A: It is comparable, with monthly costs around $13,500–$15,000, reflecting its targeted, rare-cancer niche.
Q3: What is the potential impact of biosimilars on the drug’s price?
A: Biosimilars could introduce price competition post-2030, leading to significant reductions.
Q4: How is market penetration expected to evolve?
A: It will depend on indication approvals, payer coverage, and clinician adoption, with growth expected until market saturation.
Q5: What are the main uncertainties in future revenue projections?
A: Market access delays, competitive entries, and regulatory changes.
Citations
[1] Epizyme Inc. FDA Label for Tazverik (tazemetostat), July 2020.
[2] EvaluatePharma, 2023 Global Oncology Market Data.
[3] IQVIA, US Cancer Drug Utilization Reports, 2022.
[4] Company Financials and Market Reports, Epizyme Inc., 2023.
